According to the company, the initial focus of the project will be on bovine spongiform encephalopathy; Creutzfeld-Jacob disease; type II diabetes; atherosclerosis; hepatitis; and neurodegenerative disorders such as Alzheimer's disease.
As such, Oxis said it is discussing partnerships with Claudio Soto, a researcher from the University of Texas Medical Branch; Jacek Rozga, president and CEO of Arbios Systems; Manifred Windisch, CEO of JSW Research; Noah Berkowitz, CEO of Haptoguard; and Jay Heinecke, a researcher from the University of Washington, Seattle.
Details about the discussions were not disclosed.